KORRO BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.32 USD | +15.74% |
|
+14.56% | -20.05% |
| 07-01 | Korro Bio Joins Russell 2000, 3000, Microcap Indexes | MT |
| 07-01 | Korro Bio, Inc.(NasdaqCM:KRRO) added to Russell 3000E Growth Index | CI |
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Companyâs first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
38.32
USD
Average target price
126.2
USD
Spread / Average Target
+229.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.05% | 355M | |
| +16.59% | 44.44B | |
| -10.62% | 37.68B | |
| +40.49% | 39.84B | |
| +29.92% | 31.46B | |
| -9.78% | 27.02B | |
| +12.34% | 26.29B | |
| +41.53% | 13.8B | |
| +31.49% | 12.46B | |
| -7.40% | 11.26B |
- Stock Market
- Equities
- KRRO Stock
- News Korro Bio, Inc.
- Korro Bio Joins Russell 2000, 3000, Microcap Indexes
